Based on these studies, the National Comprehensive Cancer Network (NCCN) guidelines for hereditary BC introduced in 2019 the possibility to additionally test 18 different genes, beyond BRCA1 and BRCA2. In particular, each of these genes has been classified as showing a very strong, strong, or just limited evidence for an increased risk of breast, ovarian, pancreatic and other cancers (11). This evidence concerns the gene BRCA1 and cancer.